Search clinical trials for: HGP1406

Total 59 results

1
2
›

Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501

Healthy Male Volunteers

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

Primary Hypercholesterolemia
Hanmi Pharmaceutical Company Limited

Completed

PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers

Prostatic Hyperplasia | Erectile Dysfunction
Hanmi Pharmaceutical Company Limited

Completed

Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers

Prostatic Hyperplasia | Erectile Dysfunction

Korea, Republic of
HitGen Inc.

Terminated

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Relapsed and Refractory Multiple Myeloma

China
Hanmi Pharmaceutical Company Limited

Completed

Evaluating the Bioequivalence of HIP1302, HGP1406

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers

Healthy Volunteer

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

Non-erosive Gastroesphageal Reflux Disease

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
HitGen Inc.

Recruiting

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma (HG146)

Head and Neck Cancer | Adenoid Cystic Carcinoma

China
Hanmi Pharmaceutical Company Limited

Completed

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

Benign Prostatic Hyperplasia
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel...

Completed

Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers

Healthy

United States
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers

Healthy
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects

Health, Subjective

Korea, Republic of
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Active, not recruiting

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

HIV

United States
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of HIP1601 Capsule

Erosive Gastroesophageal Reflux Disease

Korea, Republic of
Janssen Vaccines & Prevention B.V.
Beth Israel Deaconess Medical Center; US Military HIV Research Program; Ragon...

Completed

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Human Immunodeficiency Virus

United States
Hanmi Pharmaceutical Company Limited

Completed

To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers

Pulmonary Arterial Hypertension

Korea, Republic of
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Healthy

United States, South Africa, Thailand, Uganda, Rwanda
International AIDS Vaccine Initiative
Massachusetts General Hospital; GlaxoSmithKline; Fred Hutchinson Cancer Research... and other collaborators

Completed

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

HIV Infections

United States, Kenya
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines and Diagnostics, Inc

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

HIV Infections

United States
Korea University Anam Hospital

Completed

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502

Healthy

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.

Healthy

Korea, Republic of
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

Systemic Lupus Erythematosus

United States, Canada
Hanmi Pharmaceutical Company Limited

Completed

A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.

Healthy

Korea, Republic of
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057

Systemic Lupus Erythematosus

Spain, Taiwan, Germany, Russian Federation, Belgium, Philippines, Israel, Korea, Republic of, Italy, Netherlands, Sweden, Canada, Romania, Brazil, Colombia, Czechia, Mexico, United Kingdom, Argentina, Austria, India, Peru, Puerto Rico, Fran... and more
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine (ACTHIVE-001)

HIV-1-infection

Netherlands
HIV Vaccine Trials Network
South Africa AIDS Vaccine Initiative

Completed

Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults

HIV Seronegativity | HIV Preventive Vaccine

South Africa
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

HIV Infections

United States, South Africa
Assistance Publique - Hôpitaux de Paris
Human Genome Sciences Inc.

Completed

Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome (BELISS)

Sjögren's Syndrome

France
Hanmi Pharmaceutical Company Limited

Completed

Evaluating the Bioequivalence of HIP1403, HGP0919

Healthy

Korea, Republic of
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Systemic Lupus Erythematosus

United States
Hanmi Pharmaceutical Company Limited

Completed

Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions

Healthy

Korea, Republic of
HitGen Inc.

Recruiting

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Lymphoma | Solid Tumor

China
Janssen Vaccines & Prevention B.V.

Completed

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Healthy

United States, Rwanda
International AIDS Vaccine Initiative
GlaxoSmithKline; George Washington University; Amsterdam UMC, location VUmc; Rockefeller...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

HIV Infections

United States, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

HIV Infections

United States
Hanmi Pharmaceutical Company Limited

Unknown

Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

Pulmonary Hypertension | Systolic Dysfunction

Korea, Republic of

1
2
›

3

Subscribe